Skip to main content
AIMD
NASDAQ Life Sciences

Ainos Inks VELDONA License Deal Worth Up to $10M, Retains 25% Sublicensing Cut

Tom Rudovsky · Reported by ACCESS Newswire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.5
Mkt Cap
$10.301M
52W Low
$1.26
52W High
$4.44
52W Position info
19% above low
Off High info
66% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

AIMD sits 19% above its 52-week low of $1.26 on light trading volume (0.3× avg).

Summary

Ainos signed a VELDONA license agreement with BioPhoenix, establishing a collaboration framework with a potential aggregate value of $10 million. The deal covers two initial indications—Sjögren's disease and thrombocytopenia—with BioPhoenix funding and executing clinical and regulatory development. Ainos retains platform ownership, product supply opportunities, and a 25% share of net sublicensing revenue. The agreement includes a $600,000 upfront license fee due after technology transfer, a one-time first sublicense fee, and a 25% share of net sublicensing revenue. If all additional indications are licensed, total fees would be approximately $10.0 million. The $10 million is conditional and not guaranteed, but the structure reduces Ainos' need to independently fund late-stage development. This follows the company's Q2 loss of $4.6 million and going concern warning, making the partner-funded model a meaningful capital relief.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The 8-K discloses a $600,000 upfront license fee due after technology transfer, a one-time first sublicense fee, and a 25% share of net sublicensing revenue. If all additional indications are licensed, total fees would be approximately $10.0 million.

At the time of this announcement, AIMD was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $1.26 to $4.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.


Price Chart

Share this article

Copied!

AIMD - Latest Insights

AIMD
Sep 28, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.660 info
Change: -$0.728 (-52%) info
Market Cap: $4.638M info
AIMD
Sep 28, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $0.660 info
Change: -$0.660 (-50%) info
Market Cap: $4.638M info
AIMD
Sep 16, 2026, 11:00 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $0.660 info
Change: -$0.710 (-52%) info
Market Cap: $4.638M info
AIMD
Sep 14, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.50
Real-time Price: $0.660 info
Change: -$0.840 (-56%) info
Market Cap: $4.638M info
AIMD
Aug 03, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $0.660 info
Change: -$0.860 (-57%) info
Market Cap: $4.638M info